Corneal crosslinking for keratoconus Richard Keates, M.D. (PI)
Corneal crosslinking is a non-invasive (non-penetrating) procedure that increases collagen which is a natural anchor in the cornea (the front clear portion of the eye). This study will help determine if crosslinking halts the progression of keratoconus (a progressive disease that involves the thinning of the cornea) through the use of vitamin B2 drops and ultraviolet light.
You can contact Richard Keates, M.D. at richard.keates@osumc.edu with questions.
Corneal crosslinking in ectasia after refractive surgery Richard Keates, M.D. (PI)
This study will determine if vitamin B2 and ultaviolet light will halt the progression of ectasia(a progressive thinning of the cornea that sometimes follows refractive surgery, such as LASIK or PRK.)
You can contact Richard Keates, M.D. at richard.keates@osumc.edu with questions.
Rates and risk factors for fungal keratitis among contact lens wearers Thomas Mauger, M.D. (PI), Richard Lembach, M.D., Reynell Harder-Smith, D.O.
Recent reports suggest that there has been an increase in fungal keratitis amongst contact lens wearer. The CDC is conducting an ongoing investigation into whether this increase is related to contact lens solutions which have been recently pulled from the market. This study will determine if there is a link between contact lens wear and eye infections. It will also identify behavioral and environmental risk factors with a retrospective review of past cases of fungal keratitis.
You can contact Barbara Landolfi at 614-293-8760 with questions.
DYME: A double-masked, randomized study of the safety and effectiveness of DYME as an agent for selective staining of the anterior capsule during cataract surgery Thomas Mauger, M.D. (PI), Richard Lembach, M.D., Dave Castellano, M.D., Reynell Harder-Smith, D.O.
Studies have shown that using a dye during cataract surgery makes the surgery easier and the outcome better especially if the patient has a certain kind of cataract. This study analyzes whether the dye, DYME, will aid the surgeon when performing cataract surgery.
If you have a cataract and are interested in determining whether you are a candidate for this study, contact Barbara Landolfi at 614-293-8760.
Glaucoma Division is not recruiting at this time.
IIH: Idiopathic Intracranial Hypertension Clinical Study Steven K. Katz, M.D. (PI)
Idiopathic Intracranial Hypertension (IIH), also known as Pseudotumor cerebri, is a potentially blinding disorder affecting 1 in 20,000 people. The etiology is unknown; however, it is more common among obese women of childbearing age. Even though the incidence and morbidity of IIH are increasing, the treatments remain limited. The Department has partnered with the General Clinical Research Center at The OSU Medical Center to conduct a research study to identify factors (hormones/proteins) involved in IIH. Elucidating the mechanisms causing IIH will allow the development of more specific therapies for this disabling disease. The OSU Medical Center is looking for patients with suspected IIH who have NOT undergone diagnostic lumbar puncture (LP) and have NOT begun any treatment for the disease. The OSU Medical Center will coordinate and pay for the initial overnight hospital stay before the radiologically-guided LP. Patients enrolled in the study will provide samples of blood and excess cerebrospinal fluid obtained from the LP. Eligible patients will be seen on the day of contact or within several days depending on the degree of papilledema and risk of visual loss. If you have a patient that fits the following criteria, please call PRIOR to obtaining an LP or initiating treatment.
Contact Steven Katz, M.D. at 614-293-6892 or page 614-730-6223.
Contact Jill Salerno with questions about this study at 614-652-2620.
DRCR: Diabetic Retinopathy Clinical Research Network Intravitreal Ranibizumab or Triamcinolone Acetonide as Adjunctive Treatment to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy – Protocol J John Christofordis, MD (PI), Frederick H. Davidorf, MD, Susie Chang, MD
This 56 week study evaluates the effectiveness of Ranibizumab vs. Triamcinolone vs. sham as an adjunctive therapy with panretinal photocoagulation for patients who have proliferative or severe non-proliferative diabetic retinopathy who may develop diabetic macular edema. Patients will be randomized into three groups, and all will receive PRP laser. Subjects randomized into the Ranibizumab group will receive 2 injections, one at the beginning of the study and one at 4 weeks. Subjects in the Triamcinolone Acetonide group will receive an injection at the beginning of the study, and a sham injection at 4 weeks, and subjects in the sham group will receive 2 sham injections- one at the beginning of the study and one at 4 weeks.
Contact Joy Elliott with questions about this study at 614-652-2603 or r.elliott@osumc.edu.
CATT: Comparison of Age-related Macular Degeneration Treatments Trials Frederick H. Davidorf, MD (PI), Alan Letson, MD, John Christofordis, MD, Susie Chang, MD
This two year study compares Lucentis and Avastin as treatment for subfoveal neovascular AMD. Subjects will be randomized into 4 groups: (1) Lucentis on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Lucentis every 4 weeks or to variable dosing. (2) Avastin on a fixed schedule of every 4 weeks for 1 year; at 1 year, re-randomization to Avastin every 4 weeks or to variable dosing (3) Lucentis on a variable dosing schedule for 2 years; i.e., after initial treatment, monthly evaluation for treatment based on signs of lesion activity. (4) Avastin on a variable dosing schedule for 2 years; i.e., after initial treatment monthly evaluation for treatment based on signs of lesion activity.
Contact Jill Salerno regarding questions about this study at 614-652-2620 or salerno.1@osu.edu.
AREDS 2: Age-Related EYE Disease Study 2 Alan Letson, MD (PI), Frederick H. Davidorf, MD, John Christofordis, MD, L. Carol Laxson, MD, Susie Chang, MD
This study will determine if lutein, zeaxanthin and fish oil can slow or prevent the development of advanced age-related macular degeneration. Qualifying patients must have large drusen in both eyes or large drusen in one eye and advanced AMD in the fellow eye